Abstract

Diabetic sensory-motor neuropathy (DSMN) is a prevalent complication of diabetes mellitus characterized by nerve damage leading to sensory deficits, motor dysfunction, and neuropathic pain. This abstract examines the clinical and diagnostic significance of the Systemic Immune Inflammation Index (SII) in DSMN. Recent research has highlighted the association between systemic inflammation and the pathogenesis of DSMN. The SII, calculated based on peripheral blood cell counts, serves as a composite marker reflecting the balance between systemic immune responses and inflammatory status. Clinical studies have demonstrated a positive correlation between elevated SII levels of DSMN. Patients with higher SII values exhibit more pronounced neuropathy symptoms and impaired nerve conduction velocities, indicating a potential link between inflammation-mediated processes and neuropathic damage. Furthermore, the SII has emerged as a valuable diagnostic tool for predicting DSMN related inflammatory sequel and monitoring disease progression. Its non-invasive nature and cost-effectiveness make it a promising biomarker for identifying individuals at risk of developing neuropathic complications in diabetes. This abstract underscores the clinical relevance of the SII in enhancing our understanding of the inflammatory mechanisms underlying DSMN and its potential utility in early detection and management strategies. Further investigation into the predictive value and therapeutic implications of the SII in DSMN is warranted to optimize patient care and outcomes. The present study aims to evaluate the potential role of SII in predicting inflammation in patients with Diabetic Sensory-motor Neuropathy.

Description